Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients
Addiction · 2024-11 · 119 (11) · 1975-1986
DOI: 10.1111/add.16630 ↗At a glance
Beobachtungsstudie in Addiction, 2024-11. Written by Rachael K Ross and 6 co-authors. Institution: Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA. Major MEDLINE topics: Opioid-Related Disorders, Naltrexone, Delayed-Action Preparations, Buprenorphine. Cited 12 times so far (Crossref); 45 references. The full text is freely available in PubMed Central. Funded by: NIDA NIH HHS, National Institute on Drug Abuse of the National Institutes of Health, National Institute on Drug Abuse.
Topics: Sucht und Abhängigkeit
Abstract (original language)
Background and aims Extended‐release naltrexone (XR‐NTX) and sublingual buprenorphine (SL‐BUP) are both approved for opioid use disorder (OUD) treatment in any medical setting. We aimed to compare the real‐world effectiveness of XR‐NTX and SL‐BUP. Design and setting This was an observational active comparator, new user cohort study of Medicaid claims records for patients in New Jersey and California, USA, 2016–19. Participants/cases The participants were adult Medicaid patients aged 18–64 years who initiated XR‐NTX or SL‐BUP for maintenance treatment of OUD and did not use medications for OUD in the 90 days before initiation. Our cohort included 1755 XR‐NTX and 9886 SL‐BUP patients.
Measurements
We examined two outcomes up to 180 days after medication initiation: (1) composite of medication discontinuation and death and (2) composite of overdose and death.
Findings
In adjusted analyses, treatment with XR‐NTX was more likely to result in discontinuation or death by the end of follow‐up than treatment with SL‐BUP: cumulative risk 75.9% [95% confidence interval (CI) = 73.9%, 77.9%] versus 62.2% (95% CI = 61.2%, 63.2%), respectively (risk difference = 13.7 percentage points, 95% CI = 11.4, 16.0). There was minimal difference in the cumulative risk of overdose or death by the end of follow‐up: XR‐NTX 3.9% (95% CI = 3.0%, 4.8%) versus SL‐BUP 3.3% (95% CI = 2.9%, 3.7%); risk difference = 0.5 percentage points, 95% CI = –0.4, 1.5. Results were consistent across sensitivity analyses.
Conclusions
Medicaid patients in California and New Jersey, USA, receiving treatment for opioid use disorder stayed in treatment longer on sublingual buprenorphine than on extended‐release naltrexone, but the risk of overdose was similar. Most patients in this study discontinued medication within 6 months, regardless of which medication was initiated.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Epidemiology, Mailman School of Public Health, Columbia University, New York, NY, USA.
- Department of Psychiatry, Columbia University Irving Medical Center, New York, NY, USA.
- New York State Psychiatric Institute, New York, NY, USA.
- Department of Population Health, New York University, New York, NY, USA.
- Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.
ORCID profiles: Rachael K Ross, Edward V Nunes, Matisyahu Shulman, Noa Krawczyk, Kara E Rudolph
Funding
- NIDA NIH HHS
- National Institute on Drug Abuse of the National Institutes of Health
- National Institute on Drug Abuse
Cite
APA
Ross, R. K., Nunes, E. V., Olfson, M., Shulman, M., Krawczyk, N., Stuart, E. A., & Rudolph, K. E. (2024). Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients. Addiction. https://doi.org/10.1111/add.16630
Vancouver
Ross RK, Nunes EV, Olfson M, Shulman M, Krawczyk N, Stuart EA, et al. Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients. Addiction. 2024. doi:10.1111/add.16630
BibTeX
@article{Ross2024,
author = {Ross, Rachael K and Nunes, Edward V and Olfson, Mark and Shulman, Matisyahu and Krawczyk, Noa and Stuart, Elizabeth A and Rudolph, Kara E},
title = {Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients},
journal = {Addiction},
year = {2024},
doi = {10.1111/add.16630}
}
EUVIMED